Tscan Therapeutics Inc (TCRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tscan Therapeutics Inc stock (TCRX) is currently trading at $1.03. Tscan Therapeutics Inc PS ratio (Price-to-Sales) is 5.68. Analyst consensus price target for TCRX is $6.00. WallStSmart rates TCRX as Sell.
- TCRX PE ratio analysis and historical PE chart
- TCRX PS ratio (Price-to-Sales) history and trend
- TCRX intrinsic value — DCF, Graham Number, EPV models
- TCRX stock price prediction 2025 2026 2027 2028 2029 2030
- TCRX fair value vs current price
- TCRX insider transactions and insider buying
- Is TCRX undervalued or overvalued?
- Tscan Therapeutics Inc financial analysis — revenue, earnings, cash flow
- TCRX Piotroski F-Score and Altman Z-Score
- TCRX analyst price target and Smart Rating
Tscan Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tscan Therapeutics Inc (TCRX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Tscan Therapeutics Inc (TCRX) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 286.00% year-over-year
65.76% held by institutions, strong professional interest
Supporting Valuation Data
Tscan Therapeutics Inc (TCRX) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.7x annual revenue
Supporting Valuation Data
Tscan Therapeutics Inc (TCRX) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth, Institutional Own.. Valuation metrics including Price/Book (0.48) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 286.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Some valuation metrics including Price/Sales (5.68) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -71.30%, Operating Margin at -852.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -71.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 286.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TCRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TCRX's Price-to-Sales ratio of 5.68x sits near its historical average of 6.29x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 7.28x set in Mar 2026, and 0% above its historical low of 5.68x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~7.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tscan Therapeutics Inc (TCRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Tscan Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 10M with 286% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 286% YoY, reaching 10M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 194% of revenue (20M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -32M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Tscan Therapeutics Inc maintain 286%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Tscan Therapeutics Inc.
Bottom Line
Tscan Therapeutics Inc is a high-conviction growth story with revenue accelerating at 286% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(5 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:26:27 AM
About Tscan Therapeutics Inc(TCRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology firm that specializes in advancing immunotherapy through its proprietary T cell receptor (TCR) discovery platform, targeting specific cancer antigens to offer precision medicine solutions in oncology. The company is focused on developing innovative TCR-based therapeutics aimed at translating scientific advancements into effective treatment options for various cancers and diseases, ultimately improving patient outcomes. With a strong therapeutic pipeline and a comprehensive intellectual property portfolio, Tscan Therapeutics is well-positioned to become a leader in the rapidly evolving landscape of T cell-based therapies.